Spica Laboratories Profile
Key Indicators
- Authorised Capital ₹ 8.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 5.00 Cr
as on 16-11-2024
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 9.00 M
as on 16-11-2024
- Revenue 0.22%
(FY 2023)
- Profit -24.11%
(FY 2023)
- Ebitda -20.00%
(FY 2023)
- Net Worth 15.27%
(FY 2023)
- Total Assets 2.21%
(FY 2023)
About Spica Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 8.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company has closed loans amounting to ₹9.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Giridhar Thota and Shobha Thota serve as directors at the Company.
- CIN/LLPIN
U24230TG2005PTC045438
- Company No.
045438
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Feb 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Spica Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Giridhar Thota  | Director | 08-Oct-2009 | Current |
| Shobha Thota | Director | 08-Oct-2009 | Current |
Financial Performance of Spica Laboratories.
Spica Laboratories Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.22% increase. The company also saw a substantial fall in profitability, with a 24.11% decrease in profit. The company's net worth Soared by an impressive increase of 15.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Spica Laboratories?
In 2023, Spica Laboratories had a promoter holding of 91.99% and a public holding of 8.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sahasra Laboratories Private LimitedActive 18 years 7 monthsGiridhar Thota and Shobha Thota are mutual person
- Syngen Laboratories Private LimitedActive 20 years 11 months
Giridhar Thota and Shobha Thota are mutual person
- Sheetal Chemicals Private LimitedActive 20 years 5 months
Giridhar Thota and Shobha Thota are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Union Bank Of India Limited Creation Date: 28 Sep 2005 | ₹9.00 M | Satisfied |
How Many Employees Work at Spica Laboratories?
Unlock and access historical data on people associated with Spica Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Spica Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Spica Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
